FDA advisory panel votes against recommending approval of Capricor’s Duchenne cell therapy

 

FDA advisory panel votes against recommending approval of Capricor’s Duchenne cell therapy deramiocel

• Piper Sandler cut Capricor Therapeutics to Neutral and slashed its price target to $2 from $58
• Several other brokers also downgraded Capricor today following the FDA’s negative stance on deramiocel’s HOPE-3 data

https://finviz.com/stock?t=CAPR&p=d